2010 Clinical Trials Pharmaceutical Terpenes 
CannaMD
AUGUST 8, 2020
The one exception is pharmaceutical-grade CBD products that have been approved by the FDA, which currently only includes one medication: Epidiolex. Prior to receiving FDA approval, Epidiolex underwent a number of clinical trials establishing the medical efficacy of CBD. CBD Scheduling Rule Change.
Green Relief
MAY 13, 2018
As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. And in many places, cannabis is still not available as a legal therapeutic option.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 24, 2021
Research into the plant’s chemical compounds has also revealed a rich array of terpenes and flavonoids that may also account for the plant’s therapeutic effects (Kotsirilos and McGregor 2021 ). However, from 2010, a dramatic increase is observable in articles about medicinal cannabis in the publications under analysis.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Fig 1: Sucralose (In Study).
Green Relief
MAY 12, 2018
As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. And in many places, cannabis is still not available as a legal therapeutic option.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs.
Cannabis Law Report
OCTOBER 29, 2019
Wakshlag is well-known in the veterinary medicine community as the first doctor to conduct an efficacy study in dogs in a clinical trial at Cornell using ElleVet CBD/CBDA on dogs with multi-joint discomfort. The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement.
Expert insights. Personalized for you.
99 
Let's personalize your content